title: Reply to Ganesan et al.
authors: Jessica R
authors: JR
authors: Grubb
authors: Edgar Turner
authors: ET
authors: Overton
authors: Rachel
authors: R
authors: Presti
authors: Nur F
authors: NF
authors: Onen
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000401:mortality*; D015703:Antigens, CD; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008213:Lymphocyte Activation; D008297:Male; D011758:Pyrroles / Q000494:pharmacology*; D012367:RNA, Viral / Q000097:blood* / Q000187:drug effects*; D019713:Receptors, CCR5 / Q000502:physiology*; D019718:Receptors, CXCR4 / Q000502:physiology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D012367:RNA, Viral; D019713:Receptors, CCR5; D019718:Receptors, CXCR4